Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA5A | P35218 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | MMP12 | P39900 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.51 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.49 |
| ▸ | APLNR | P35414 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.47 |
| ▸ | CMA1 | P23946 | 1/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4028531 | 0.84 | CA12 (0.56) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL17225939 | 0.82 | PTGS2 (0.72) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL31540563 | 0.81 | CA12 (0.53) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL2115708 | 0.81 | CA1 (0.62) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL3298473 | 0.80 | APLNR (0.52) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL28854259 | 0.79 | MMP8 (0.54) | CA12CA1CA2CA5ACA9 | |
| Hydrochloric Acid SCHEMBL20551658 | 0.79 | RECQL (0.61) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL18249746 | 0.79 | ALDH1A1 (0.54) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL30137221 | 0.78 | AOC3 (0.51) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL14770119 | 0.78 | CA12 (0.50) | CA12CA1CA2CA5ACA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2897599-B1 | SUBSTITUTED ALKYL DIARYL DERIVATIVES, METHODS OF PREPARATION AND USES | UNIV TEMPLE (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3227262-B1 | SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS INC (US) | 2020-05-13 | — | — | EP | disclosed |
| CN-110776447-A | Substituted alkyl diaryl derivatives, preparation method and use | 坦普尔大学 | 2020-02-11 | — | — | CN | disclosed |
| US-10428041-B2 | Pyridyl reverse sulfonamides for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190152940-A1 | Pyridyl Reverse Sulfonamides For HBV Treatment | NOVIRA THERAPEUTICS, INC. | 2019-05-23 | — | — | US | disclosed |
| US-10207989-B2 | Substituted alkyl diaryl derivatives, methods of preparation and uses | Temple University—Of the Commonwealth System of Higher Education (US) | 2019-02-19 | — | — | US | disclosed |
| US-10160742-B2 | Pyridyl reverse sulfonamides for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180051000-A1 | Pyridyl Reverse Sulfonamides For HBV Treatment | NOVIRA THERAPEUTICS, INC. | 2018-02-22 | — | — | US | disclosed |
| CN-107406378-A | Sulfurized alkyl compounds and pyridine trans sulfonamide compounds for HBV treatment | 诺维拉治疗公司 | 2017-11-28 | — | — | CN | disclosed |
| EP-3227262-A1 | SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT | Novira Therapeutics Inc. (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20160185748-A1 | PYRIDYL REVERSE SULFONAMIDES FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
| WO-2016089990-A1 | SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| US-20150266819-A1 | SUBSTITUTED ALKYL DIARYL DERIVATIVES, METHODS OF PREPARATION AND USES | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2015-09-24 | — | — | US | disclosed |
| EP-2897599-A2 | SUBSTITUTED ALKYL DIARYL DERIVATIVES, METHODS OF PREPARATION AND USES | Temple University - Of The Commonwealth System of Higher Education (US) | 2015-07-29 | — | — | EP | disclosed |
| CN-104812382-A | Substituted alkyl diaryl derivatives, preparation method and use | UNIV TEMPLE | 2015-07-29 | — | — | CN | disclosed |
| WO-2014047110-A2 | SUBSTITUTED ALKYL DIARYL DERIVATIVES, METHODS OF PREPARATION AND USES | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-03-27 | — | — | WO | disclosed |
| US-5561112-A | ADMINISTERING SMALL SYNTHETIC PEPTIDES(SIMILAR TO GLYCINE-ASPARTIC ACID) TO SUPPRESS THROMBOSIS | SANDOZ LTD. (CH) | 1996-10-01 | — | — | US | disclosed |
| EP-0560730-B1 | New derivatives of beta-amino acids with anti-thrombotic activity | SANDOZ LTD (CH) | 1996-09-11 | — | — | EP | disclosed |
| EP-0560730-A2 | New derivatives of beta-amino acids with anti-thrombotic activity | SANDOZ LTD. (CH) | 1993-09-15 | — | — | EP | disclosed |
| CN-1076200-A | NEW DERIVATIVES OF BETA-AMINO ACIDS | SANDOZ LTD (CH) | 1993-09-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152940-A1 | Pyridyl Reverse Sulfonamides For HBV Treatment | HAVCR2, HCCS, NR1H4 | CA12 3206/4885CA1 4332/4885CA2 3736/4885 |
| US-10428041-B2 | Pyridyl reverse sulfonamides for HBV treatment | HAVCR2, HCCS, NR1H4 | CA12 3206/4885CA1 4332/4885CA2 3736/4885 |
| US-20180051000-A1 | Pyridyl Reverse Sulfonamides For HBV Treatment | HAVCR2, HCCS, NR1H4 | CA12 3206/4885CA1 4332/4885CA2 3736/4885 |
| US-20150266819-A1 | SUBSTITUTED ALKYL DIARYL DERIVATIVES, METHODS OF PREPARATION AND USES | CCNY, CCNB3, BOD1L1 | CA12 3702/4885CA1 3536/4885CA2 3228/4885 |
| US-10160742-B2 | Pyridyl reverse sulfonamides for HBV treatment | HAVCR2, HCCS, NR1H4 | CA12 3206/4885CA1 4332/4885CA2 3736/4885 |
| US-10207989-B2 | Substituted alkyl diaryl derivatives, methods of preparation and uses | CCNY, CCNB3, BOD1L1 | CA12 3702/4885CA1 3536/4885CA2 3228/4885 |
| US-20160185748-A1 | PYRIDYL REVERSE SULFONAMIDES FOR HBV TREATMENT | HAVCR2, HCCS, NR1H4 | CA12 3206/4885CA1 4332/4885CA2 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.